Back to Search
Start Over
Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD
- Source :
- Clinical Lymphoma Myeloma and Leukemia. 20:690-696
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Background Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cytarabine and methotrexate (hyper-CVAD) is a commonly used regimen in adults with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). Adult patients fit for pediatric-inspired protocols have an excellent outcome with chemotherapy alone. However, it is unclear whether patients receiving hyper-CVAD should undergo allogeneic hematopoietic cell transplantation (HCT) as postremission therapy. Our aim was to examine the role of HCT at first complete remission (CR1) in adult ALL/LBL after hyper-CVAD. Patients and Methods Adult patients with newly diagnosed ALL/LBL receiving frontline hyper-CVAD from 2008 to 2018 were identified and records retrospectively extracted. Results A total of 85 patients were identified and included for further analysis. The median (range) age was 23 (14-68) years, and 56 (66%) were male. A total of 24 (28%) had adverse cytogenetics, and 48 (56%) had at least one risk factor. All patients received hyper-CVAD as induction; induction failure was seen in 10 (12%). A total of 38 patients continued the hyper-CVAD course, while the remaining 47 received HCT in CR1. Three-year event-free survival (EFS) and overall survival for the entire cohort were 51.4% and 61.6%, respectively. Median follow-up of alive patients was 39.9 (3.8-123.8) months. At multivariable analysis for EFS, induction failure was associated with worse outcome (hazard ratio [HR], 4.8; 95% confidence interval [CI] 1.7-13.7; P = .003), whereas HCT in CR1 improved outcome (HR, 0.42; 95% CI 0.18-0.97; P = .044). Furthermore, HCT in CR1 was the only prognostic factor for overall survival (HR, 0.3; 95% CI 0.11-0.85; P = .023). Conclusion HCT at CR1 resulted in a favorable EFS and overall survival in ALL/LBL patients after hyper-CVAD frontline therapy. Given that hyper-CVAD is a widely used protocol for adult patients, further examination of this observation is warranted.
- Subjects :
- Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Vincristine
Transplantation Conditioning
Adolescent
Cyclophosphamide
Hyper-CVAD
Dexamethasone
Young Adult
03 medical and health sciences
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Aged
business.industry
Lymphoblastic lymphoma
Hazard ratio
Hematopoietic Stem Cell Transplantation
Hematology
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma
medicine.disease
Transplantation
Regimen
Doxorubicin
030220 oncology & carcinogenesis
Cytarabine
Female
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 21522650
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Clinical Lymphoma Myeloma and Leukemia
- Accession number :
- edsair.doi.dedup.....73e3ebdb8c976415926ab4a3dad5702b
- Full Text :
- https://doi.org/10.1016/j.clml.2020.05.012